Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of glucose for cellular metabolism, primarily via glycolysis and the Krebs cycle, to produce ATP. Sodium chloride maintains fluid and electrolyte balance, acting as a source of sodium and chloride ions essential for osmotic pressure and acid-base homeostasis.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Fluid and electrolyte replacement in patients with hypotonic dehydration,Maintenance of hydration and electrolyte balance,Provision of calories in patients requiring parenteral nutrition
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion: 100-200 m L/hour per 70 kg adult; rate adjusted based on fluid and electrolyte needs, typically 0.5-4 m L/kg/hour.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable; dextrose and electrolytes are endogenous substances, not subject to classic elimination half-life. Plasma glucose half-life is ~15-20 minutes in euglycemic conditions due to rapid cellular uptake.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose undergoes cellular metabolism via glycolysis and the Krebs cycle; sodium and chloride are renally excreted and regulated by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Dextrose: primarily metabolized to CO2 and water; <1% excreted unchanged renally. Sodium chloride: electrolytes are reabsorbed or excreted renally; no specific elimination pathway.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
None (0%): dextrose and sodium chloride are not bound to plasma proteins.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: Vd ~0.2 L/kg (limited to extracellular fluid); sodium distributes primarily in extracellular fluid (Vd ~0.15-0.3 L/kg).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% (complete bioavailability). Not applicable for other routes.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR <30 m L/min: Reduce infusion rate by 50-75% and monitor serum sodium; avoid in anuria.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class B or C: No specific dose adjustment required; monitor for fluid overload and hyponatremia.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion: 0.5-4 m L/kg/hour, adjusted based on maintenance fluid requirements (e.g., 4-2-1 rule) and clinical status.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower end of infusion rate (e.g., 0.5-1 m L/kg/hour) due to decreased renal function and higher risk of fluid overload; monitor serum sodium and volume status.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None.
None.
Monitor serum glucose, electrolytes, and fluid balance regularly,Risk of hyperglycemia in diabetic patients,Volume overload in patients with heart failure or renal impairment,Extravasation risk during IV administration,May cause electrolyte imbalances with prolonged use
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperglycemia or glucose intolerance,Hypernatremia or hyperchloremia,Severe renal impairment with oliguria,Severe dehydration (avoid hypotonic solutions in shock),Known allergy to any component
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No direct food interactions with this IV solution. However, oral intake may affect electrolyte balance; patients on sodium restriction should avoid high-sodium foods.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose and sodium chloride at these concentrations are generally not teratogenic. Glucose is a physiologic nutrient and sodium chloride is an electrolyte; no fetal risks are reported when used appropriately. Trimester risk: Category C (not shown to be harmful, but no controlled studies).
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Compatible with breastfeeding. Dextrose and sodium chloride are normal blood constituents. M/P ratio not applicable; both compounds transfer into breast milk in negligible amounts without adverse effects.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy increases plasma volume, possibly requiring higher volumes of IV fluids. Pharmacokinetic changes: increased GFR may affect electrolyte excretion; dose adjustments are not typically needed but individualize based on maternal hydration status and serum glucose/electrolytes.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This solution provides 85 m Eq/L sodium and 77 m Eq/L chloride. Use with caution in patients with heart failure, renal impairment, or hypertension due to sodium load. Monitor serum electrolytes and fluid balance. Not for peripheral administration if osmolarity >900 m Osm/L (this solution is isotonic). Assess injection site for phlebitis or extravasation.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This intravenous solution provides fluids and electrolytes, not food calories.,Report any signs of fluid overload: swelling, shortness of breath, or rapid weight gain.,Inform your healthcare provider if you have high blood pressure, heart problems, or kidney issues.,Tell your nurse immediately if you experience pain, redness, or swelling at the IV site.,This solution contains sodium; follow any dietary sodium restrictions as advised by your doctor.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of glucose for cellular metabolism, primarily via glycolysis and the Krebs cycle, to produce ATP. Sodium chloride maintains fluid and electrolyte balance, acting as a source of sodium and chloride ions essential for osmotic pressure and acid-base homeostasis.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion: 100-200 m L/hour per 70 kg adult; rate adjusted based on fluid and electrolyte needs, typically 0.5-4 m L/kg/hour.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride at these concentrations are generally not teratogenic. Glucose is a physiologic nutrient and sodium chloride is an electrolyte; no fetal risks are repo. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.